Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing acute therapies for the treatment of episodic cardiovascular indications, announced yesterday that it has named Michael Tomsicek as its director.
Presently, Tomsicek is the chief financial officer of biopharmaceutical company, CRISPR Therapeutics. At Milestone he will also serve as chairman of the board's Audit Committee.
Tomsicek has more than 20 years of corporate and financial leadership experience to Milestone. Prior to joining CRISPR, he served as the chief financial officer of Abiomed. He has also served as chief financial officer at Cubist Pharmaceuticals, where he held various roles in financial operations, investor relations, and corporate strategy. During his tenure at Cubist, he participated in the transition of the company following its acquisition by Merck. He also served in a series of financial leadership positions at General Electric Healthcare, where he oversaw the global ultrasound business.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer